SCHEMBL6320

SCHEMBL6320

COc1ccc(Br)c([N+](=O)[O-])c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.55
MAPK1 P28482 5/20 0.55
MAPT P10636 8/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
KDM4E B2RXH2 2/20 0.50
PKM P14618 2/20 0.50
G6PD P11413 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
APOBEC3G Q9HC16 1/20 0.50
CYP2D6 P10635 1/20 0.50
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
HTT P42858 2/20 0.47
GAA P10253 3/20 0.47
AKR1C3 P42330 1/20 0.47
AKR1C2 P52895 1/20 0.47
POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30585356 1.00 ALDH1A1 (0.55) ALDH1A1MAPK1MAPTMEN1KMT2A
SCHEMBL30199709 0.87 ALDH1A1 (0.53) ALDH1A1MAPK1MAPTMEN1KMT2A
SCHEMBL228082 0.87 ALDH1A1 (0.53) ALDH1A1MAPK1MAPTMEN1KMT2A
SCHEMBL1662886 0.82 ALDH1A1 (0.65) ALDH1A1MAPK1MAPTMEN1KMT2A
SCHEMBL12992246 0.81 ALDH1A1 (0.41) ALDH1A1MAPK1MAPTMEN1KMT2A
SCHEMBL10340370 0.81 ALDH1A1 (0.61) ALDH1A1MAPK1MAPTMEN1KMT2A
SCHEMBL8211036 0.81 ALDH1A1 (0.46) ALDH1A1MAPK1MAPTMEN1KMT2A
SCHEMBL9157246 0.81 MAPT (0.62) ALDH1A1MAPK1MAPTMEN1KMT2A
SCHEMBL15541009 0.80 MAPT (0.48) ALDH1A1MAPK1MAPTMEN1KMT2A
SCHEMBL3501410 0.80 ALDH1A1 (0.48) ALDH1A1MAPK1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 575 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118791392-A Method for synthesizing melarsoprol and intermediate compound 华中科技大学 2024-10-18 CN claimed
CN-118702588-A Preparation method of ilast and intermediate thereof 重庆华邦胜凯制药有限公司 2024-09-27 CN claimed
CN-117143097-A Beta-carbopol compound, preparation method thereof and application of beta-carbopol compound in resisting Alzheimer disease 中国人民解放军北部战区总医院 2023-12-01 CN claimed
CN-119431405-B Indolo [3,2-b ] carbazole dimer derivative, and preparation method and application thereof 沈阳药科大学 2026-05-15 CN disclosed
US-20250368667-A1 USP1 INHIBITOR SHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE LTD (CN) 2025-12-04 US disclosed
EP-4631573-A2 TEAD INHIBITORS Orion Corporation (FI) 2025-10-15 EP disclosed
EP-4323338-B1 TEAD INHIBITORS ORION CORP (FI) 2025-10-08 EP disclosed
US-20250270215-A1 IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2025-08-28 US disclosed
EP-4582427-A1 USP1 INHIBITOR Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) 2025-07-09 EP disclosed
US-20250195668-A1 BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES THE BROAD INSTITUTE, INC. 2025-06-19 US disclosed
US-20250171447-A1 ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF MERCK SHARP & DOHME LLC (US) 2025-05-29 US disclosed
WO-1998038991-A1 POLYCYCLIC ETHYL ALKYLAMIDE MELATONERGIC AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 1998-09-11 WO disclosed
WO-1998012190-A2 PHENOXATHIIN DERIVATIVES AS INHIBITORS OF MONOAMINE OXIDASE KRENITSKY PHARMACEUTICAL, INC. (US) 1998-03-26 WO disclosed
US-5677328-A SLEEP DISORDERS; PSYCHOLOGICAL DISORDERS BRISTOL-MYERS SQUIBB COMPANY (US) 1997-10-14 US disclosed
EP-0771791-A1 Ethylamino carbazole melatonergic agents BRISTOL-MYERS SQUIBB COMPANY (US) 1997-05-07 EP disclosed
US-5576324-A Quinoline derivatives or salt thereof and remedy for cardiac diseases containing the same KOWA CO., LTD. (JP) 1996-11-19 US disclosed
US-5461046-A Analgesics G. D. SEARLE & CO. (US) 1995-10-24 US disclosed
EP-0638571-A1 QUINOLINE DERIVATIVE OR SALT THEREOF AND REMEDY FOR CARDIAC DISEASES CONTAINING THE SAME KOWA CO. LTD. (JP) 1995-02-15 EP disclosed
US-5304644-A 1-,2-,3-,4-,5-,6-,7-,8- and/or 9 substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain G. D. SEARLE & CO. (US) 1994-04-19 US disclosed
WO-1994003425-A2 CARBOSTYRIL DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIA SYNTEX (U.S.A.) INC. (US) 1994-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171447-A1 ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF ADORA2A, ADORA2B, ADORA1 ALDH1A1 483/4885MAPK1 3063/4885MAPT 4454/4885
US-20250195668-A1 BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES COASY, JMJD7, PTMS ALDH1A1 1238/4885MAPK1 3733/4885MAPT 3572/4885
US-20250368667-A1 USP1 INHIBITOR USP1, USP2, USP28 ALDH1A1 644/4885MAPK1 1205/4885MAPT 2468/4885
US-20250270215-A1 IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS ALK, TGFBR1, TGFBR2 ALDH1A1 828/4885MAPK1 277/4885MAPT 2205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.